These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28434413)

  • 1. DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.
    Gilabert-Perramon A; Torrent-Farnell J; Catalan A; Prat A; Fontanet M; Puig-Peiró R; Merino-Montero S; Khoury H; Goetghebeur MM; Badia X
    Int J Technol Assess Health Care; 2017 Jan; 33(1):111-120. PubMed ID: 28434413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
    Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
    BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Step Toward the Development of the First National Multi-Criteria Decision Analysis Framework to Support Healthcare Decision Making in Saudi Arabia.
    Al-Jedai A; Almudaiheem H; Alruthia Y; Althemery A; Alabdulkarim H; Ojeil R; Alrumaih A; AlGhannam S; AlMutairi A; Hasnan Z
    Value Health Reg Issues; 2024 May; 41():100-107. PubMed ID: 38306770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?
    Baran-Kooiker A; Czech M; Kooiker C
    Front Public Health; 2018; 6():287. PubMed ID: 30374435
    [No Abstract]   [Full Text] [Related]  

  • 5. Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.
    Wagner M; Khoury H; Willet J; Rindress D; Goetghebeur M
    Pharmacoeconomics; 2016 Mar; 34(3):285-301. PubMed ID: 26547306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs.
    Alnaqbi KA; Elezbawy B; Fasseeh AN; Bangash AR; Elshamy A; Shendi H; Aftab MI; AlMarshoodi M; Gebran N; AlDhaheri N; Fahmy SA; Al Dallal S; Al Naeem W; Abaza S; Kaló Z
    Cureus; 2024 Feb; 16(2):e55215. PubMed ID: 38558740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
    Kolasa K; Zwolinski KM; Kalo Z; Hermanowski T
    Orphanet J Rare Dis; 2016 Mar; 11():23. PubMed ID: 26965710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.
    Schey C; Postma MJ; Krabbe PFM; Topachevskyi O; Volovyk A; Connolly M
    Front Public Health; 2020; 8():162. PubMed ID: 32457865
    [No Abstract]   [Full Text] [Related]  

  • 9. The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review.
    Su P; Zhi K; Xu H; Xiao J; Liu J; Wang Z; Liu Q; Yu Y; Dang H
    Front Pharmacol; 2024; 15():1245825. PubMed ID: 38720775
    [No Abstract]   [Full Text] [Related]  

  • 10. Design of a multiple criteria decision analysis framework for prioritizing high-impact health technologies in a regional health service.
    Sánchez-Martínez FI; Abellán-Perpiñán JM; Martínez-Pérez JE; Gómez-Torres JL
    Int J Technol Assess Health Care; 2024 Apr; 40(1):e21. PubMed ID: 38576122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of relevant information around non-core domains to support Multi-Criteria Decision Analysis (MCDA) for decision making.
    Bayón-Yusta JC; Gutiérrez-Iglesias A; Galnares-Cordero L; Gutiérrez-Ibarluzea I
    GMS Health Innov Technol; 2024; 18():Doc02. PubMed ID: 38655192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment.
    Angelis A; Kanavos P
    Pharmacoeconomics; 2016 May; 34(5):435-46. PubMed ID: 26739955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating vonoprazan and tegoprazan for gastroesophageal reflux disease treatment in Chinese Healthcare: an EVIDEM framework analysis.
    Xue C; Du Y; Yang H; Jin H; Zhao Y; Ren B; Dong Z
    BMC Gastroenterol; 2024 Jun; 24(1):208. PubMed ID: 38902604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience.
    Laba TL; Jiwani B; Crossland R; Mitton C
    Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32762789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Societal Preferences in Health Technology Assessments for Rare Diseases and Orphan Drugs: A Systematic Literature Review of New Analytic Approaches.
    Vásquez P; Hall L; Merlo G
    Value Health Reg Issues; 2024 Jul; 44():101026. PubMed ID: 39059264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-criteria decision analysis approach for strategy scale-up with application to Chagas disease management in Bolivia.
    Pinazo MJ; Cidoncha A; Gopal G; Moriana S; Saravia R; Torrico F; Gascon J
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009249. PubMed ID: 33770076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of concerted and hospital hemodialysis through a multi-criteria decision analysis.
    Caro Martínez A; Valcárcel Cabrera MDC; Olry de Labry Lima A
    Nefrologia (Engl Ed); 2023; 43(6):742-749. PubMed ID: 38246811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
    Abad MR; Alerany C; Alsina L; Granados EL; Neth O; Poveda JL; Rivière JG; Rodríguez-Gallego C; Tutein Nolthenius JB; Figueiredo R; Labazuy SS; Gil A
    Glob Reg Health Technol Assess; 2024; 11():124-130. PubMed ID: 38784663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing neuro-oncology clinical trial impact and value: Testing a novel multi-criteria decision analysis app.
    Field KM; Andrew Rosenthal M; Gillett P; IJzerman M
    J Clin Neurosci; 2023 Dec; 118():70-78. PubMed ID: 37890196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
    Pereyra-Rodríguez JJ; Poveda JL; Rivero A; Serra-Baldrich E; Silvestre JF; Armario-Hita JC; Calleja MÁ; Carrascosa JM; Flórez Á; Herranz P; Comellas M; Ortiz de Frutos FJ
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e59-e62. PubMed ID: 37594914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.